Retatrutide 10mg Vial ( No labels yet )

FOR RESEARCH PURPOSES ONLY .

Preclinical Animal Research

Diet-Induced Obese Mouse Model

Study objective

Researchers investigated the effects of retatrutide in mice with diet-induced obesity and metabolic dysfunction-associated steatohepatitis (MASH), a preclinical model commonly used to study obesity and metabolic disease.

Methods

Male mice were fed a high-fat diet to induce obesity before receiving retatrutide treatment. Researchers monitored:

* Body weight
* Food intake
* Body composition
* Insulin resistance
* Liver fat accumulation
* Blood lipid concentrations
* Energy expenditure

Results

Compared with untreated controls, researchers observed:

* 31% reduction in body weight during the treatment period.
* Significant reductions in fat mass, with some reduction in lean mass.
* Marked decreases in food intake during the initial days of treatment.
* Significant improvements in insulin resistance (measured using HOMA-IR).
* Reduced liver fat accumulation and hepatic steatosis.
* Lower liver triglyceride and cholesterol content.

Interestingly, in this particular study, energy expenditure was not significantly increased, suggesting that the observed weight loss in this model was driven primarily by reduced food intake rather than a measurable rise in metabolic rate.

⸻

Hamster Model

The same investigators also evaluated retatrutide in obese hamsters maintained on a high-fat, high-cholesterol dietary model.

Researchers observed

* Reduced preference for calorie-dense food.
* Increased consumption of standard chow.
* Reduced intake of fructose-containing water.
* Significant body weight reduction.
* Preservation of bone mineral density after five weeks of treatment despite weight loss.

⸻

Mechanistic Mouse Studies

Separate preclinical studies have examined how retatrutide acts at its three target receptors (GLP-1, GIP and glucagon).

Researchers reported:

* Reduced gastric emptying.
* Improved glucose handling.
* Reduced body weight.
* Alterations in nutrient utilisation and whole-body metabolism in obese mouse models.

These studies suggest that simultaneous activation of all three receptors produces broader metabolic effects than activation of the GLP-1 receptor alone.